Lantus/Lixisenatide Combo Gets FDA Panel Nod, But Not Sanofi's Device
This article was originally published in The Pink Sheet Daily
Executive Summary
Pen for iGlarLixi should be redesigned to reduce risk of confusion and medication errors, advisory committee members say.
You may also be interested in...
Novo Nordisk, Sanofi Insulin Combo Products Clear US Regulatory Hurdles
US FDA approves Xultophy and Soliqua, both fixed-ratio combinations of a basal insulin and a GLP-1 agonist, on the same day even though Sanofi redeemed a priority review voucher that earned Soliqua an earlier user fee goal date.
Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems
FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.
Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago
The latest drug development news and highlights from our FDA Performance Tracker.